Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.
Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.
OrthoPediatrics is a medical device company focused on the pediatric orthopedic market, dedicated to improving the treatment of children's orthopedic conditions. The company designs, develops, and manufactures a range of orthopedic implants and instruments tailored specifically for pediatric orthopedic surgeons and small stature patients. Its product lineup includes innovative offerings such as PediLoc, PediPlates, Cannulated Screws, PediFlex nail, and the PediNail, among others. OrthoPediatrics aims to enhance surgical outcomes by providing anatomically appropriate solutions that address the unique needs of its patients, thereby advancing the field of pediatric orthopedics. The company also emphasizes the importance of reducing anxiety during procedures, as demonstrated by its QCR technology, which operates quietly and minimizes vibration while effectively cutting through casting materials.
STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing products for dermatological conditions in the United States and Asia. The company operates two main segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its key products include the XTRAC excimer laser and VTRAC lamp systems, which are designed to treat skin disorders such as psoriasis, vitiligo, atopic dermatitis, and eczema. Additionally, STRATA offers the MelaFind system to aid in the identification and management of melanoma skin cancer. The company distributes its products both internationally through distributors and domestically directly to physicians. Founded in 1989, STRATA Skin Sciences is headquartered in Horsham, Pennsylvania.
Marco Capital, Inc. is a trade finance platform headquartered in Miami, Florida, that aims to provide small and medium-sized exporters from Latin America with access to working capital. Established in 2019, the platform facilitates investments in short-term trade finance receivables between Latin American exporters and U.S. importers. It promotes paperless processes, allowing users to upload documents and invoices seamlessly. The platform also incorporates support from industry experts and leverages artificial intelligence to streamline financing services and trade operations. Marco Capital focuses on simplifying the financing experience for businesses, enabling them to save time and foster growth.
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.
Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.
Aterian is a technology-driven consumer products company that specializes in building, acquiring, and partnering with various brands. Founded in 2014, Aterian operates a diverse range of product categories, including home and kitchen appliances, kitchenware, environmental appliances, beauty products, and consumer electronics. The company utilizes proprietary software and an agile supply chain to efficiently create and market top-selling consumer products. Aterian manages several owned brands, such as Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. With a global presence that includes offices in America, Canada, Poland, Israel, China, and the Philippines, as well as remote employees in France, Australia, and Croatia, Aterian focuses on generating revenue primarily through online sales of its various consumer products.
Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.
LendingPoint LLC is a financial technology company based in Kennesaw, Georgia, with additional offices in New York and Nevada. Founded in 2014, it specializes in providing online consumer loans through a cloud-based lending platform that employs predictive risk algorithms. LendingPoint offers personal loans for various purposes, including debt consolidation, home improvement, credit card refinancing, and medical expenses. Additionally, the company operates LendingPoint Merchant Solutions, which provides financing options for merchants, service providers, and medical institutions. The firm's services extend to e-commerce and point-of-sale financing, leveraging advanced fraud prevention and risk management strategies to create financing opportunities across the credit spectrum.
Digital Reasoning Systems, Inc. specializes in developing artificial intelligence solutions that automate the analysis and organization of unstructured data for businesses. Founded in 2000 and headquartered in Franklin, Tennessee, the company offers its flagship product, Synthesys, which utilizes advanced features such as natural language processing and entity resolution to categorize and link data effectively. This platform is designed to provide critical insights and intelligence for various sectors, including government, finance, healthcare, and legal markets. Digital Reasoning’s solutions help clients visualize connections within data sets, enhancing their ability to identify risks and threats. The company also maintains strategic partnerships to expand its offerings and reach. Additional offices are located in New York, Washington, D.C., and London.
Arboretum Investment Advisors, LLC specializes in providing financing and investment advisory services focused on fundamental capital assets that are essential to middle-market companies globally. The firm manages funds that offer asset-backed financing, emphasizing non-correlated, income-producing investment strategies to diversify investor portfolios. In addition to financing, Arboretum is involved in asset management and asset servicing, catering specifically to the needs of its clients in the middle-market sector.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing peptide-based product candidates to meet unmet medical needs in hematology and gastroenterology. The company is advancing several key products, including PTG-300, an injectable hepcidin mimetic in Phase II clinical trials for treating beta-thalassemia-related anemia, and PTG-200, an antagonist peptide that has completed Phase I trials aimed at moderate-to-severe Crohn's disease. Additionally, PN-943, an oral integrin antagonist, is in Phase I trials for inflammatory bowel disease. Protagonist also explores both oral and injectable peptide candidates for various gastrointestinal conditions. The company has established a collaboration with Janssen Biotech for the development and commercialization of PTG-200. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California.
Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.
Organogenesis Holdings Inc. is a regenerative medicine company that specializes in developing, manufacturing, and commercializing solutions for advanced wound care and surgical and sports medicine, primarily in the United States. The company's advanced wound care products include Apligraf and Dermagraft for treating diabetic foot ulcers and venous leg ulcers, as well as PuraPly AM, Affinity, and NuShield for various wound types. In the surgical and sports medicine sector, Organogenesis offers products like ReNu for joint and tendon applications and NuCel for spinal and extremity fusion. The company also has a pipeline of products, including TransCyte for burns and Gintuit for mucogingival conditions. Organogenesis serves a range of healthcare facilities, including hospitals and wound care centers, distributing its products through direct sales and independent agencies. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has made significant contributions to the field of regenerative medicine, having received FDA approvals for several of its innovative therapies.
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.
Kashable LLC operates an online platform that provides employer-sponsored voluntary benefit programs, focusing on financial wellness for employees. Founded in 2013 and based in New York, the company allows eligible employees to apply for loans online, facilitating access to affordable financing for managing debt or covering unexpected expenses. The platform enables automatic repayment through structured payroll deductions, ensuring a seamless experience for users. By offering socially responsible financing options, Kashable aims to support employees in achieving better financial stability while providing employers with a valuable benefit to enhance their employee assistance programs.
The Credit Junction is the first data-driven asset-based lending platform and is transforming the way small and mid-size businesses access working capital, growth, and supply chain financing solutions. The company combines technology and data intelligence with traditional asset-based credit metrics and offers up to $7.5 million in capital availability. The Credit Junction targets growth-oriented suppliers, distributors, and manufacturers typically with revenues between $5M and $50M. It was founded in 2014 and is headquartered in New York, United States.
ZPower, LLC is a developer and manufacturer of rechargeable silver-zinc micro batteries, primarily serving the hearing aid, medical device, and portable electronics markets. Founded in 1996 and based in Camarillo, California, the company offers a range of products, including various models of rechargeable micro batteries and charging systems for hearing aids. ZPower's advanced battery technology aims to enhance product development for manufacturers and improve performance for end-users, promoting a better user experience and environmental sustainability. The company filed for reorganization under Chapter 11 in March 2020, indicating ongoing challenges in its operations.
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Sarepta Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery and development of precision genetic medicines for rare diseases. Founded in 1980, the company specializes in innovative approaches such as gene therapy, RNA-targeted exon skipping, and gene editing. With a focus on rapid development, Sarepta targets a variety of diseases by employing proprietary RNA-targeted technology platforms to create novel pharmaceutical products. The company addresses significant unmet medical needs while most of its product candidates remain in the early stages of development. Additionally, Sarepta utilizes third-party contractors for the manufacturing of its therapeutics.
Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.
Oxford Immunotec is a medical diagnostics company specializing in the development of novel tests for various diseases through its patented T cell measurement technology. The company has pioneered the T-SPOT.TB test, an interferon gamma release assay designed to diagnose latent tuberculosis infection and active TB disease, serving as a modern alternative to the traditional Mantoux skin test. In addition to its focus on tuberculosis, Oxford Immunotec is dedicated to advancing proprietary diagnostic tests for a range of underserved immune-regulated conditions, including chronic infections, transplantation, autoimmune and inflammatory diseases, and immune oncology. Through its innovative approach, the company aims to enhance the management of these conditions and improve patient outcomes.
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.
Having funded over $200 million is small business loans; IOU Financial has the experience to help any business get what they need. They have offices all over the world and the knowledge and flexibility to get your business the capital it needs to seize the growth opportunities that will help you realize their potential
Spectra7 Microsystems is a semiconductor company delivering unprecedented bandwidth, speed, and resolution to enable disruptive industrial design for leading consumer electronics manufacturers in virtual reality, augmented reality, data centers, and other connectivity markets. It specializes in the fields of wireless infrastructure and data center active cables.
Spectranetics is a medical technology company based in Colorado that specializes in developing single-use tools for minimally invasive cardiovascular surgeries. The company focuses on lead management, as well as peripheral and coronary interventions, offering advanced products such as scoring balloon technology and laser atherectomy. Spectranetics provides healthcare providers with innovative solutions and proven algorithms to effectively manage cardiac leads, modify plaque, and address complications like restenosis and amputation. With a commitment to product innovation, Spectranetics continually explores new methods to enhance the effectiveness and efficiency of complex cardiovascular procedures, ultimately aiming to improve patient outcomes and quality of life.
Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.
Quotient Biodiagnostics is focused on providing high quality, high value immunohematology products to hospitals and blood banks in the US. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.
Aventine Renewable Energy Holdings is a prominent producer of corn-based fuel-grade ethanol and related by-products. The company specializes in the production and marketing of renewable fuels, which serve as gasoline additives and contribute to reducing dependence on foreign oil. Aventine's facilities focus on generating low carbon renewable fuels, including ethanol and various co-products, which also help offset a substantial portion of corn costs. By supplying these products to major energy and food companies in the United States and globally, Aventine plays a significant role in promoting environmental sustainability and improving automobile performance.
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.
Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, that specializes in the design, development, and commercialization of devices for gastrointestinal therapeutic endoscopy. Founded in 2005, the company offers a range of innovative products aimed at reducing the need for invasive surgical procedures. Key offerings include the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which allow physicians to place full-thickness sutures through a flexible endoscope, and the X-Tack Endoscopic HeliX Tacking System. Additionally, Apollo provides the Orbera Intragastric Balloon, which helps manage obesity by reducing stomach capacity. The company's solutions are designed to lower complication rates and overall healthcare costs, making them valuable tools for gastroenterologists and bariatric surgeons. Apollo Endosurgery distributes its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians across the United States, Brazil, Australia, and various European countries.
Quotient Biodiagnostics is focused on providing high quality, high value immunohematology products to hospitals and blood banks in the US. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies.
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.